<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20120125008819N3</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2022-12-12</date_registration>
      <primary_sponsor>Tehran University of Medical Sciences</primary_sponsor>
      <public_title>Comparison of the efficacy of Chamomile and Myrtus ointment in comparison with anti-hemorrhoid ointment</public_title>
      <acronym></acronym>
      <scientific_title>Investigating the efficacy of herbal ointment (Chamomile and Myrtus) compared to anti-hemorrhoid ointment in the treatment of patients with hemorrhoids in a randomized clinical trial</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2022-12-22</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>100</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/67069</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Single blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: Patients will be allocated to the intervention and control groups using the block randomization method (block of 4). Randomization will be done centrally and before the initiation of the study by someone who is not directly involved in the recruitment of participants. Those who enroll patients in the study will not know the order of allocations. A senior researcher and clinical trial supervisor prepare a patient allocation plan based on the randomization list. Group codes of new patients will be handed over in separate sealed envelopes to the senior field researcher. So, the allocation of new patients to the groups will be hidden and will not be predictable, Blinding description: Due to the products' characteristics, it is impossible to blind the patient in this study, and the study is conducted as a single-blind study. The researcher who evaluate the outcomes will not be aware of the medication received by the patients. In other words, the assignment of patients to groups and handing the drugs to patients will be done by another researcher.</study_design>
      <phase>3</phase>
      <hc_freetext>Hemorrhoids.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: Rectal ointment containing Myrtle and Chamomile: In the intervention group, Rectus® ointment (produced by Iran Darouk Company) is used rectally, one applicator (containing one gram of the ointment) twice a day for two weeks. Every 30 grams (one tube) of Rectus® Ointment contains 8.1 grams of standardized essential oil of Myrtus communis and 0.3 grams of dried Matricaria chamomilla extract. Intervention 2: Control group: Rectal ointment of anti-hemorrhoids: Patients assigned to the control group receive anti-hemorrhoid ointment (produced by Aburihan company) rectally, one applicator (containing one gram of the ointment) twice a day for two weeks. Anti-hemorrhoid ointment contains hydrocortisone acetate (2.75 mg/g), lidocaine (50 mg/g), aluminum subacetate (35 mg/g) and zinc oxide (180 mg/g).</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is Currently, the team of researchers have not decided on this issue.</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Mona Kargar</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>4th floor, No: 92, South Kheradmand Junction, Karimkhan-e-zand Ave</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1584775315</zip>
        <telephone>+98 21 8881 4157</telephone>
        <email>mkargar@razi.tums.ac.ir</email>
        <affiliation>Tehran University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Foroogh Alborzi Avanaki</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Chamran highway, Bagherkhan St. ,Imam Khomeini Hospital Complex</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>۱۴۱۹۷۳۳۱۴۱</zip>
        <telephone>+98 21 6119 0000</telephone>
        <email>foroogh1983@yahoo.com</email>
        <affiliation>Tehran University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Age between 20 to 65 years
Hemorrhoid grade 1-2 based on the BPRST definition</inclusion_criteria>
      <agemin>20 years</agemin>
      <agemax>65 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Hemorrhoid requiring surgery
External thrombosed and strangulated hemorrhoid
Anal fistula
Anal fisher
Anal abscess
Portal hypertension
Pregnancy
Breastfeeding
History of inflammatory bowel diseases
History of gastrointestinal malignancy
Severe and acute cardiovascular disease
Severe and acute liver disease
Renal failure
Asthma
Using oral corticosteroids
Food or inhalation allergy needs medication therapy
Use of the current research medications
Rectal use of medications with the same active ingredient as the research medications</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>K64</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Hemorrhoids and perianal venous thrombosis</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: Rectal ointment containing Myrtle and Chamomile: In the intervention group, Rectus® ointment (produced by Iran Darouk Company) is used rectally, one applicator (containing one gram of the ointment) twice a day for two weeks. Every 30 grams (one tube) of Rectus® Ointment contains 8.1 grams of standardized essential oil of Myrtus communis and 0.3 grams of dried Matricaria chamomilla extract.</i_keyword>
      <i_keyword>Control group: Rectal ointment of anti-hemorrhoids: Patients assigned to the control group receive anti-hemorrhoid ointment (produced by Aburihan company) rectally, one applicator (containing one gram of the ointment) twice a day for two weeks. Anti-hemorrhoid ointment contains hydrocortisone acetate (2.75 mg/g), lidocaine (50 mg/g), aluminum subacetate (35 mg/g) and zinc oxide (180 mg/g).</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Severity of hemorrhoid signs/symptoms including bleeding, persistent pain, pain during defecation, anal itching, and tenesmus. Timepoint: Before, one week, andtwo weeks after the initiation of the study. Method of measurement: The presence and severity of each of the signs/symptoms (from 1 to 10)  based on taking a history.</prim_outcome>
      <prim_outcome>Severity of hemorrhoid symptoms considering their interferences with daily activity (Scores 0-3). Timepoint: Before and two weeks after the initiation of the study. Method of measurement: History taking ( 0=no symptoms, 1=symptoms without any effects on daily activity, 2= symptoms that affects daily activity, 3=  Severe interference with daily activity).</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Iran Darouk Pharmaceutical-Cosmetic Company</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2022-10-18</approval_date>
        <contact_name>Ethics committee of Imam Khomeini Hospital Complex, Tehran University of Medical Sciences</contact_name>
        <contact_address>Imam Khomeini Hospital Complex, Bagherkhan St., Chamran highway Tehran Tehran Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
